Compass Associates
Multi-award-winning recruitment consultancy dedicated to the independent Health, Social Care and Children's Services sectors.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Brilinta (ticagrelor) to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischaemic attack (TIA).